FDA Clarifies Oversight Exception For Stem Cell Procedures
The U.S. Food and Drug Administration on Thursday described when surgeries involving human tissues, stem cells and similar living materials are considered a single procedure that qualifies for relaxed oversight, the...To view the full article, register now.
Already a subscriber? Click here to view full article